What’s the current market cap for Asker Healthcare Group AB stock?

Asker Healthcare Group AB (ASKER) has a market cap of Skr29bn as of June 17, 2026.

What is the P/E ratio for Asker Healthcare Group AB stock?

The price to earnings (P/E) ratio for Asker Healthcare Group AB (ASKER) stock is 46.94 as of June 17, 2026.

Does Asker Healthcare Group AB stock pay dividends?

Yes, the Asker Healthcare Group AB (ASKER) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is Skr0.39 and the yield is 0.51%. Asker Healthcare Group AB has a payout ratio of 0% on a trailing twelve-month basis.

When is the next Asker Healthcare Group AB dividend payment date?

The next Asker Healthcare Group AB (ASKER) dividend payment date is unconfirmed.

What is the beta indicator for Asker Healthcare Group AB?

Asker Healthcare Group AB (ASKER) does not currently have a Beta indicator.

Buy Asker Healthcare Group AB stock | SkrASKER Share Price

07:00

09:05

11:15

13:20

15:25

About Asker Healthcare Group AB

Asker Healthcare Group AB operates in the healthcare industry, focusing on providing medical supplies, services, and equipment primarily to healthcare institutions. The company is involved in the distribution and logistics of medical consumables and advanced medical technology products. Headquartered in Sweden, Asker Healthcare Group serves markets across Europe, leveraging its extensive network to cater to hospitals, care homes, and other healthcare service providers. The company emphasizes efficient supply chain management and aims to support healthcare professionals with reliable product accessibility and quality service, ensuring continuity in patient care.

Ticker

Skr ASKER

Sector

Health

Primary listing

XSTO

Employees

4,781

Headquarters

Danderyd, Sweden

Website

www.asker.com

ASKER Metrics

BasicAdvanced

kr 29bn

46.94

kr 1.63

kr 0.39

0.51%

Bulls say / Bears say

Strong Q1 2026 performance with net sales up 13% and adjusted EBITA up 21%, driving margin expansion to 9.8% and sending shares up 8.93%, evidencing robust operational momentum (Investing.com).

Executive Emma Rheborg’s insider purchase of SEK 0.7 million in shares signals management’s confidence in the company’s growth prospects (TradingView/Reuters).

Strategic acquisition of RMS Medical Devices in Belgium enhances Asker’s European distribution network and diversifies its advanced diagnostics product portfolio (TradingView/Reuters).

Discontinuation of the Hardam acquisition in Denmark underscores potential M&A integration and due diligence challenges in Asker’s aggressive acquisition strategy (TradingView/Reuters).

Debt-to-EBITDA remains elevated at approximately 3.2x, which could limit financial flexibility and increase vulnerability to interest rate fluctuations (StockAnalysis).

Issuance of call options to the Chair at a strike 20% above the current share price may exert downward pressure on the stock if exercised, raising potential dilution concerns (Cision).

Data summarised monthly by Lightyear AI. Last updated on 13 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Skr ASKER

Skr

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Strong Q1 2026 performance with net sales up 13% and adjusted EBITA up 21%, driving margin expansion to 9.8% and sending shares up 8.93%, evidencing robust operational momentum (Investing.com).

Executive Emma Rheborg’s insider purchase of SEK 0.7 million in shares signals management’s confidence in the company’s growth prospects (TradingView/Reuters).

Strategic acquisition of RMS Medical Devices in Belgium enhances Asker’s European distribution network and diversifies its advanced diagnostics product portfolio (TradingView/Reuters).

Discontinuation of the Hardam acquisition in Denmark underscores potential M&A integration and due diligence challenges in Asker’s aggressive acquisition strategy (TradingView/Reuters).

Debt-to-EBITDA remains elevated at approximately 3.2x, which could limit financial flexibility and increase vulnerability to interest rate fluctuations (StockAnalysis).

Issuance of call options to the Chair at a strike 20% above the current share price may exert downward pressure on the stock if exercised, raising potential dilution concerns (Cision).

Data summarised monthly by Lightyear AI. Last updated on 13 Jun 2026.

About Asker Healthcare Group AB

Ticker

Primary listing

Employees

Headquarters

ASKER Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr ASKER

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Asker Healthcare Group AB/Skr ASKER

About Asker Healthcare Group AB

Ticker

Primary listing

Employees

Headquarters

ASKER Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr ASKER

Upcoming events

No upcoming events

What’s the current market cap for Asker Healthcare Group AB stock?

What is the P/E ratio for Asker Healthcare Group AB stock?

Does Asker Healthcare Group AB stock pay dividends?

When is the next Asker Healthcare Group AB dividend payment date?

What is the beta indicator for Asker Healthcare Group AB?

Bulls say / Bears say